seen with concurrent use. .brexanoloneMonitor Closely (1)brexanolone, trifluoperazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazoleMonitor Closely (1)brexpiprazole and trifluoperazine both increase sedation. Use Caution/Monitor.brimonidineMonitor Closely (1)brimonidine and trifluoperazine both increase sedation. Use Caution/Monitor.Minor (1)brimonidine increases effects of trifluoperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.brivaracetamMonitor Closely (1)brivaracetam and trifluoperazine both increase sedation. Use Caution/Monitor.bromocriptineSerious - Use Alternative (1)trifluoperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.brompheniramineMonitor Closely (1)brompheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.buprenorphineMonitor Closely (2)buprenorphine and trifluoperazine both increase sedation. Use Caution/Monitor. buprenorphine and trifluoperazine both decrease QTc interval. Use Caution/Monitor.buprenorphine buccalMonitor Closely (1)buprenorphine buccal and trifluoperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine buccal and trifluoperazine both decrease QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantMonitor Closely (2)buprenorphine subdermal implant and trifluoperazine both decrease QTc interval. Use Caution/Monitor. buprenorphine subdermal implant and trifluoperazine both increase sedation. Use Caution/Monitor.buprenorphine transdermalMonitor Closely (2)buprenorphine transdermal and trifluoperazine both decrease QTc interval. Use Caution/Monitor. buprenorphine transdermal and trifluoperazine both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionMonitor Closely (3)trifluoperazine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate. buprenorphine, long-acting injection and trifluoperazine both decrease QTc interval. Use Caution/Monitor. buprenorphine, long-acting injection and trifluoperazine both increase sedation. Use Caution/Monitor.bupropionMonitor Closely (1)bupropion will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Minor (1)trifluoperazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible.butabarbitalMonitor Closely (1)butabarbital and trifluoperazine both increase sedation. Use Caution/Monitor.butalbitalMonitor Closely (1)butalbital and trifluoperazine both increase sedation. Use Caution/Monitor.butorphanolMonitor Closely (1)butorphanol and trifluoperazine both increase sedation. Use Caution/Monitor.cabergolineSerious - Use Alternative (1)trifluoperazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.caffeineMonitor Closely (1)trifluoperazine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.calcium/magnesium/potassium/sodium oxybatesSerious - Use Alternative (1)trifluoperazine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.cannabidiolMonitor Closely (1)cannabidiol, trifluoperazine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition with the coadministration of CYP1A2 substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate.captoprilMinor (1)trifluoperazine increases effects of captopril by unspecified interaction mechanism. Minor/Significance Unknown. Both drugs lower blood pressure. Monitor blood pressure.carbinoxamineMonitor Closely (1)carbinoxamine and trifluoperazine both increase sedation. Use Caution/Monitor.carisoprodolMonitor Closely (1)carisoprodol and trifluoperazine both increase sedation. Use Caution/Monitor.celecoxibMinor (1)celecoxib will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.cenobamateMonitor Closely (1)cenobamate, trifluoperazine. Either increases effects of the other by sedation. Use Caution/Monitor.chasteberryMinor (1)chasteberry decreases effects of trifluoperazine by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).chloral hydrateMonitor Closely (1)chloral hydrate and trifluoperazine both increase sedation. Use Caution/Monitor.chlordiazepoxideMonitor Closely (1)chlordiazepoxide and trifluoperazine both increase sedation. Use Caution/Monitor.chloroquineMinor (2)chloroquine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown. chloroquine increases levels of trifluoperazine by decreasing metabolism. Minor/Significance Unknown.chlorpheniramineMonitor Closely (1)chlorpheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.chlorpromazineMonitor Closely (2)chlorpromazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. chlorpromazine and trifluoperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)chlorpromazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.chlorzoxazoneMonitor Closely (1)chlorzoxazone and trifluoperazine both increase sedation. Use Caution/Monitor.cigarette smokingMonitor Closely (1)cigarette smoking decreases levels of trifluoperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.cimetidineMinor (1)cimetidine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.cinnarizineMonitor Closely (1)cinnarizine and trifluoperazine both increase sedation. Use Caution/Monitor.cisatracuriumMonitor Closely (3)cisatracurium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. cisatracurium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.clarithromycinSerious - Use Alternative (1)trifluoperazine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.clemastineMonitor Closely (1)clemastine and trifluoperazine both increase sedation. Use Caution/Monitor.clomipramineMonitor Closely (1)trifluoperazine and clomipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)clomipramine, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. clomipramine, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.clonazepamMonitor Closely (1)clonazepam and trifluoperazine both increase sedation. Use Caution/Monitor.clonidineMonitor Closely (1)clonidine, trifluoperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateMonitor Closely (1)clorazepate and trifluoperazine both increase sedation. Use Caution/Monitor.clozapineMonitor Closely (2)clozapine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. clozapine and trifluoperazine both increase sedation. Use Caution/Monitor.codeineMonitor Closely (1)codeine and trifluoperazine both increase sedation. Use Caution/Monitor.cyclizineMonitor Closely (4)cyclizine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. cyclizine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. cyclizine and trifluoperazine both increase sedation. Use Caution/Monitor.cyclobenzaprineMonitor Closely (4)cyclobenzaprine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. cyclobenzaprine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. cyclobenzaprine and trifluoperazine both increase sedation. Use Caution/Monitor.cyproheptadineMonitor Closely (1)cyproheptadine and trifluoperazine both increase sedation. Use Caution/Monitor.dantroleneMonitor Closely (1)dantrolene and trifluoperazine both increase sedation. Use Caution/Monitor.daridorexantMonitor Closely (1)trifluoperazine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacinMonitor Closely (3)darifenacin decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. darifenacin decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)darifenacin will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.dasatinibMonitor Closely (1)trifluoperazine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.degarelixSerious - Use Alternative (1)degarelix and trifluoperazine both decrease QTc interval. Avoid or Use Alternate Drug.desfluraneMonitor Closely (2)desflurane and trifluoperazine both decrease QTc interval. Use Caution/Monitor. desflurane and trifluoperazine both increase sedation. Use Caution/Monitor.desipramineMonitor Closely (1)trifluoperazine and desipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)desipramine, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. desipramine, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.desvenlafaxineMonitor Closely (1)desvenlafaxine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mgdeutetrabenazineMonitor Closely (3)trifluoperazine and deutetrabenazine both increase sedation. Use Caution/Monitor. trifluoperazine and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics. deutetrabenazine and trifluoperazine both decrease QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniramineMonitor Closely (1)dexchlorpheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.dexfenfluramineMonitor Closely (2)trifluoperazine, dexfenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidineMonitor Closely (1)dexmedetomidine and trifluoperazine both increase sedation. Use Caution/Monitor.dexmethylphenidateMonitor Closely (2)trifluoperazine, dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetamineMonitor Closely (2)trifluoperazine, dextroamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextromethorphanMonitor Closely (1)dextromethorphan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dextromoramideMonitor Closely (1)dextromoramide and trifluoperazine both increase sedation. Use Caution/Monitor.diamorphineMonitor Closely (1)diamorphine and trifluoperazine both increase sedation. Use Caution/Monitor.diazepamMonitor Closely (1)diazepam and trifluoperazine both increase sedation. Use Caution/Monitor.dicyclomineMonitor Closely (3)dicyclomine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. dicyclomine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diethylpropionMonitor Closely (2)trifluoperazine, diethylpropion. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalinMonitor Closely (1)difelikefalin and trifluoperazine both increase sedation. Use Caution/Monitor.difenoxin hclMonitor Closely (1)difenoxin hcl and trifluoperazine both increase sedation. Use Caution/Monitor.dihydroergotamineMonitor Closely (1)dihydroergotamine, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dimenhydrinateMonitor Closely (1)dimenhydrinate and trifluoperazine both increase sedation. Use Caution/Monitor.diphenhydramineMonitor Closely (4)diphenhydramine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. diphenhydramine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. diphenhydramine and trifluoperazine both increase sedation. Use Caution/Monitor.Minor (1)diphenhydramine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.diphenoxylate hclMonitor Closely (1)diphenoxylate hcl and trifluoperazine both increase sedation. Use Caution/Monitor.dipipanoneMonitor Closely (1)dipipanone and trifluoperazine both increase sedation. Use Caution/Monitor.disopyramideContraindicated (1)trifluoperazine and disopyramide both increase QTc interval. Contraindicated.dobutamineMonitor Closely (2)trifluoperazine, dobutamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dofetilideSerious - Use Alternative (1)trifluoperazine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.dolasetronMonitor Closely (1)trifluoperazine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezilMonitor Closely (1)donepezil and trifluoperazine both decrease QTc interval. Use Caution/Monitor.donepezil transdermalMonitor Closely (1)donepezil transdermal, trifluoperazine. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dopamineMonitor Closely (2)trifluoperazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine decreases effects